Search results for:
mirvetuximab soravtansine
mirvetuximab soravtansine
Drug Name |
Form |
Strength |
ARHS |
Blue Ridge |
Caldwell |
Chatham |
Johnston |
Lenoir |
Medical Center |
Nash |
Pardee |
Rex |
Rockingham |
Southeastern |
Wayne |
Youth Behavioral Health |
Mirvetuximab Soravtansine-gynx |
SOLUTION, INTRAVENOUS |
5 mg/mL (20 mL) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Last updated: Sep. 29, 2023
UNC Health
Caution – Category 1: Antineoplastic Hazardous Medication, see below for exposure mitigation strategies
System Formulary Restriction:
Use of mirvetuximab soravtansine injection is restricted to outpatient encounters or clinic use only (ie, no inpatient use)
Mirvetuximab soravtansine orders must be signed by a Hematology/Oncology/Gynecology-Oncology Attending Physician
Med Center
UNC Medical Center Formulary Restrictions